Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02757326 · OUTCOME

To Assess the Antitumor Activity of Single Agent Opaganib in Patients With Refractory or Relapsed Multiple Myeloma After 3 Cycles of Treatment.

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma · Source last updated 2021-06-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
After 3 cycles (12 weeks) of treatment

What was measured

Stable disease, partial response, complete response or disease progression.

Analysis population: Intent to treat

Groups in this outcome

ABC294640 250 mg BID

ABC294640 250 mg BID given continuously

ABC294640 500 mg BID

ABC294640 250 mg BID given continuously

ABC294640 750 mg BID

ABC294640 750 mg BID given continuously

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ABC294640 250 mg BID3
ABC294640 500 mg BID4
ABC294640 750 mg BID6

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ABC294640 250 mg BID0Not reportedNot reportedNot reportedNot reported
ABC294640 500 mg BID2Not reportedNot reportedNot reportedNot reported
ABC294640 750 mg BID0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        2
      3. group Id
        OG002
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      6
    units
    Participants
description
Stable disease, partial response, complete response or disease progression.
groups
  1. description
    ABC294640 250 mg BID given continuously
    id
    OG000
    title
    ABC294640 250 mg BID
  2. description
    ABC294640 250 mg BID given continuously
    id
    OG001
    title
    ABC294640 500 mg BID
  3. description
    ABC294640 750 mg BID given continuously
    id
    OG002
    title
    ABC294640 750 mg BID
param Type
COUNT_OF_PARTICIPANTS
population Description
Intent to treat
reporting Status
POSTED
time Frame
After 3 cycles (12 weeks) of treatment
title
To Assess the Antitumor Activity of Single Agent Opaganib in Patients With Refractory or Relapsed Multiple Myeloma After 3 Cycles of Treatment.
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice